#United States #New York #Neogen Corporation #securities claims #FDA Warning

Neogen's Stock Faces Investigation Following FDA Warning

Neogen Corporation (NASDAQ: NEOG) recently faced a severe downturn, with its stock losing up to 7.22% following an alarming warning from the FDA regarding its product, HYCOAT. This equine product, marketed for its sterility, has come under fire due to reports of fungal contamination that has led to serious health issues in horses, including nearly 100 affected cases and at least 20 actual deaths.

The decline in stock price appears to have occurred without any coinciding earnings report, with Neogen's next financial disclosure not scheduled until October 6. This lack of earnings guidance has made the stock's drop particularly striking. Various financial outlets, including The Chronicle-Journal and TradingView, reported extensively on this unsettling sell-off, highlighting the potential risks for investors.

Reasons for the Stock Sell-off

The root cause of this sell-off appears to be the pending investigation into the nutritional supplement HYCOAT, which was supposed to provide safety and health benefits for equine customers. Instead, FDA tests revealed multiple species of fungi within the product, casting serious doubt on the quality control measures employed by Neogen.

With such severe allegations surfacing, SueWallSt.com has reached out to investors who may have bought NEOG shares at inflated prices, urging them to report any losses experienced due to this unfortunate scandal. In a preliminary analysis, they indicated a potentially substantial number of investors may be eligible to seek compensation for their losses.

Ongoing Investigation

The investigation led by SueWallSt is aimed at potential securities law violations linked to these events. Questions are being raised regarding whether Neogen misled its investors about the quality and safety of its products. With the FDA's action now public, it’s becoming more evident that the statements issued prior could have misled investors into believing that they were buying into a safe and stable investment when, in fact, the truth about HYCOAT's safety was drastically different.

The investigation brings forth several crucial questions:

• - How much did NEOG stock drop?

Shares unexpectedly fell approximately 7.22%, directly linked to the FDA's warning about the contaminated product.

• - Which statements are under scrutiny?

The investigation focuses on material representations concerning product safety, primarily within the Animal Safety segment, including the Neogen Vet product line.

• - What should NEOG investors do next?

Interested investors are encouraged to gather brokerage records detailing their transactions and submit this information for an evaluation of potential recovery options available to them.

Questions for Investors

Investors now have a series of questions to consider:

• - What documents do I need?

Investors will need brokerage statements that validate purchase dates, quantities, and prices paid for shares.

• - Can I still recover losses if I've sold?

Yes, eligibility is based on purchase timing, so those who sold shares will still have the opportunity to partake in the investigation.

• - Is there a cost to participate?

There are no upfront costs associated with submitting information for review, and should further legal actions be pursued, they will generally operate on a contingency basis.

The public has yet to determine how harshly Neogen might be impacted by these developments, including potential fines and litigation costs. With growing concerns unfolding about product safety, the stakes are particularly high. As always, maintaining up-to-date awareness regarding the health of stocks like Neogen is essential for investors.

For thorough analysis and legal support, investors are urged to contact attorney Joseph E. Levi, Esq. at (888) SueWallSt for further guidance regarding their claims. Neogen is now positioned at a critical juncture as it navigates this troubling period amidst increasing scrutiny from regulatory and legal authorities.